EUROPEAN UROLOGY, vol.59, no.4, pp.526-540, 2011 (SCI-Expanded)
Article / Article
Science Citation Index Expanded (SCI-EXPANDED), Scopus
Metastatic renal cell cancer, Targeted agents, Toxicity, RENAL-CELL CARCINOMA, ANGIOGENESIS INHIBITOR BEVACIZUMAB, ENDOTHELIAL GROWTH-FACTOR, INTERFERON-ALPHA, EUROPEAN-SOCIETY, DOUBLE-BLIND, TASK-FORCE, SORAFENIB, SUNITINIB, RISK
Dokuz Eylül University Affiliated:
Context: The therapeutic scenario for metastatic renal cell carcinoma (mRCC) has been evolving rapidly, with sunitinib, sorafenib, bevacizumab, everolimus, pazopanib, and temsirolimus being successfully tested and approved in a short period of time. Oncologists must be familiar with the management of toxicity that these biologic agents cause, as such toxicity is different from that of conventional chemotherapeutic agents.